Skip to main content
Top
Published in: Archives of Virology 3/2024

01-03-2024 | Vaccination | Review

Correlates of immune protection against human rotaviruses: natural infection and vaccination

Authors: Tayebeh Latifi, Atefeh Kachooei, Somayeh Jalilvand, Saman Zafarian, Farzin Roohvand, Zabihollah Shoja

Published in: Archives of Virology | Issue 3/2024

Login to get access

Abstract

Species A rotaviruses are the leading viral cause of acute gastroenteritis in children under 5 years of age worldwide. Despite progress in the characterization of the pathogenesis and immunology of rotavirus-induced gastroenteritis, correlates of protection (CoPs) in the course of either natural infection or vaccine-induced immunity are not fully understood. There are numerous factors such as serological responses (IgA and IgG), the presence of maternal antibodies (Abs) in breast milk, changes in the intestinal microbiome, and rotavirus structural and non-structural proteins that contribute to the outcome of the CoP. Indeed, while an intestinal IgA response and its surrogate, the serum IgA level, are suggested as the principal CoPs for oral rotavirus vaccines, the IgG level is more likely to be a CoP for parenteral non-replicating rotavirus vaccines. Integrating clinical and immunological data will be instrumental in improving rotavirus vaccine efficacy, especially in low- and middle-income countries, where vaccine efficacy is significantly lower than in high-income countries. Further knowledge on CoPs against rotavirus disease will be helpful for next-generation vaccine development. Herein, available data and literature on interacting components and proposed CoPs against human rotavirus disease are reviewed, and limitations and gaps in our knowledge in this area are discussed.
Literature
2.
go back to reference Afchangi A, Arashkia A, Shahosseini Z, Jalilvand S, Marashi SM, Roohvand F, Mohajel N, Shoja Z (2018) Immunization of mice by rotavirus NSP4-VP6 fusion protein elicited stronger responses compared to VP6 alone. Viral Immunol 31:233–241PubMedCrossRef Afchangi A, Arashkia A, Shahosseini Z, Jalilvand S, Marashi SM, Roohvand F, Mohajel N, Shoja Z (2018) Immunization of mice by rotavirus NSP4-VP6 fusion protein elicited stronger responses compared to VP6 alone. Viral Immunol 31:233–241PubMedCrossRef
3.
go back to reference Afchangi A, Latifi T, Jalilvand S, Marashi SM, Shoja Z (2021) Combined use of lactic-acid-producing bacteria as probiotics and rotavirus vaccine candidates expressing virus-specific proteins. Adv Virol 166:995–1006 Afchangi A, Latifi T, Jalilvand S, Marashi SM, Shoja Z (2021) Combined use of lactic-acid-producing bacteria as probiotics and rotavirus vaccine candidates expressing virus-specific proteins. Adv Virol 166:995–1006
4.
go back to reference Afchangi A, Jalilvand S, Arashkia A, Latifi T, Farahmand M, Shirazi MMA, Nasab SDM, Marashi SM, Roohvand F, Shoja Z (2022) Co-administration of rotavirus nanospheres VP6 and NSP4 proteins enhanced the anti-NSP4 humoral responses in immunized mice. Microb Pathog 163:105405PubMedCrossRef Afchangi A, Jalilvand S, Arashkia A, Latifi T, Farahmand M, Shirazi MMA, Nasab SDM, Marashi SM, Roohvand F, Shoja Z (2022) Co-administration of rotavirus nanospheres VP6 and NSP4 proteins enhanced the anti-NSP4 humoral responses in immunized mice. Microb Pathog 163:105405PubMedCrossRef
5.
go back to reference Ali A, Kazi AM, Cortese MM, Fleming JA, Moon S, Parashar UD, Jiang B, McNeal MM, Steele D, Bhutta Z (2015) Impact of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine—a randomized trial. PLoS ONE 10:e0127622PubMedPubMedCentralCrossRef Ali A, Kazi AM, Cortese MM, Fleming JA, Moon S, Parashar UD, Jiang B, McNeal MM, Steele D, Bhutta Z (2015) Impact of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine—a randomized trial. PLoS ONE 10:e0127622PubMedPubMedCentralCrossRef
6.
go back to reference Amin AB, Tate JE, Waller LA, Lash TL, Lopman BA (2023) Monovalent rotavirus vaccine efficacy against different rotavirus genotypes: a pooled analysis of phase II and III Trial data. Clin Infect Dis 76:e1150–e1156PubMedCrossRef Amin AB, Tate JE, Waller LA, Lash TL, Lopman BA (2023) Monovalent rotavirus vaccine efficacy against different rotavirus genotypes: a pooled analysis of phase II and III Trial data. Clin Infect Dis 76:e1150–e1156PubMedCrossRef
7.
go back to reference Angel J, Franco MA, Greenberg HB (2007) Rotavirus vaccines: recent developments and future considerations. Nat Rev Microbiol 5:529–539PubMedCrossRef Angel J, Franco MA, Greenberg HB (2007) Rotavirus vaccines: recent developments and future considerations. Nat Rev Microbiol 5:529–539PubMedCrossRef
8.
go back to reference Angel J, Steele AD, Franco MA (2014) Correlates of protection for rotavirus vaccines: possible alternative trial endpoints, opportunities, and challenges. Hum Vaccin Immunother 10:3659–3671PubMedPubMedCentralCrossRef Angel J, Steele AD, Franco MA (2014) Correlates of protection for rotavirus vaccines: possible alternative trial endpoints, opportunities, and challenges. Hum Vaccin Immunother 10:3659–3671PubMedPubMedCentralCrossRef
9.
go back to reference Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA (2010) Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. The Lancet 376:606–614CrossRef Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA (2010) Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. The Lancet 376:606–614CrossRef
10.
go back to reference Azevedo MP, Vlasova AN, Saif LJ (2013) Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease. Expert Rev Vaccines 12:169–181PubMedCrossRef Azevedo MP, Vlasova AN, Saif LJ (2013) Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease. Expert Rev Vaccines 12:169–181PubMedCrossRef
11.
go back to reference Baker JM, Tate JE, Leon J, Haber MJ, Pitzer VE, Lopman BA (2020) Postvaccination serum antirotavirus immunoglobulin A as a correlate of protection against rotavirus gastroenteritis across settings. J Infect Dis 222:309–318PubMedPubMedCentralCrossRef Baker JM, Tate JE, Leon J, Haber MJ, Pitzer VE, Lopman BA (2020) Postvaccination serum antirotavirus immunoglobulin A as a correlate of protection against rotavirus gastroenteritis across settings. J Infect Dis 222:309–318PubMedPubMedCentralCrossRef
12.
go back to reference Bennett A, Pollock L, Jere KC, Pitzer VE, Lopman B, Bar-Zeev N, Iturriza-Gomara M, Cunliffe NA (2020) Duration and density of fecal rotavirus shedding in vaccinated Malawian children with rotavirus gastroenteritis. J Infect Dis 222:2035–2040PubMedCrossRef Bennett A, Pollock L, Jere KC, Pitzer VE, Lopman B, Bar-Zeev N, Iturriza-Gomara M, Cunliffe NA (2020) Duration and density of fecal rotavirus shedding in vaccinated Malawian children with rotavirus gastroenteritis. J Infect Dis 222:2035–2040PubMedCrossRef
13.
go back to reference Bergman H, Henschke N, Hungerford D, Pitan F, Ndwandwe D, Cunliffe N, Soares-Weiser K (2021) Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2019:CD008521 Bergman H, Henschke N, Hungerford D, Pitan F, Ndwandwe D, Cunliffe N, Soares-Weiser K (2021) Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2019:CD008521
14.
go back to reference Bernstein DI, Sander DS, Smith VE, Schiff GM, Ward RL (1991) Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis 164:277–283PubMedCrossRef Bernstein DI, Sander DS, Smith VE, Schiff GM, Ward RL (1991) Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis 164:277–283PubMedCrossRef
15.
go back to reference Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N, Kawade A, Kang G, Rathore SS, Juvekar S, Muliyil J, Arya A, Shaikh H, Abraham V, Vrati S, Proschan M, Kohberger R, Thiry G, Glass R, Greenberg HB, Curlin G, Mohan K, Harshavardhan GV, Prasad S, Rao TS, Boslego J, Bhan MK, India Rotavirus Vaccine G (2014) Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 383:2136–2143PubMedPubMedCentralCrossRef Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N, Kawade A, Kang G, Rathore SS, Juvekar S, Muliyil J, Arya A, Shaikh H, Abraham V, Vrati S, Proschan M, Kohberger R, Thiry G, Glass R, Greenberg HB, Curlin G, Mohan K, Harshavardhan GV, Prasad S, Rao TS, Boslego J, Bhan MK, India Rotavirus Vaccine G (2014) Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 383:2136–2143PubMedPubMedCentralCrossRef
16.
go back to reference Bines JE, Danchin M, Jackson P, Handley A, Watts E, Lee KJ, West A, Cowley D, Chen MY, Barnes GL, Justice F, Buttery JP, Carlin JB, Bishop RF, Taylor B, Kirkwood CD (2015) Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 15:1389–1397PubMedCrossRef Bines JE, Danchin M, Jackson P, Handley A, Watts E, Lee KJ, West A, Cowley D, Chen MY, Barnes GL, Justice F, Buttery JP, Carlin JB, Bishop RF, Taylor B, Kirkwood CD (2015) Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 15:1389–1397PubMedCrossRef
17.
go back to reference Bines JE, At Thobari J, Satria CD, Handley A, Watts E, Cowley D, Nirwati H, Ackland J, Standish J, Justice F, Byars G, Lee KJ, Barnes GL, Bachtiar NS, Viska Icanervilia A, Boniface K, Bogdanovic-Sakran N, Pavlic D, Bishop RF, Kirkwood CD, Buttery JP, Soenarto Y (2018) Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from birth. N Engl J Med 378:719–730PubMedPubMedCentralCrossRef Bines JE, At Thobari J, Satria CD, Handley A, Watts E, Cowley D, Nirwati H, Ackland J, Standish J, Justice F, Byars G, Lee KJ, Barnes GL, Bachtiar NS, Viska Icanervilia A, Boniface K, Bogdanovic-Sakran N, Pavlic D, Bishop RF, Kirkwood CD, Buttery JP, Soenarto Y (2018) Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from birth. N Engl J Med 378:719–730PubMedPubMedCentralCrossRef
18.
go back to reference Bishop RF, Barnes GL, Cipriani E, Lund JS (1983) Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 309:72–76PubMedCrossRef Bishop RF, Barnes GL, Cipriani E, Lund JS (1983) Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 309:72–76PubMedCrossRef
19.
go back to reference Bishop RF, Bugg HC, Masendyez PJ, Lund JS, Gorrell RJ, Barnes GL (1996) Serum, fecal, and breast milk rotavirus antibodies as indices of infection in mother-infant pairs. J Infect Dis 174:S22–S29PubMedCrossRef Bishop RF, Bugg HC, Masendyez PJ, Lund JS, Gorrell RJ, Barnes GL (1996) Serum, fecal, and breast milk rotavirus antibodies as indices of infection in mother-infant pairs. J Infect Dis 174:S22–S29PubMedCrossRef
20.
21.
go back to reference Britto C, Alter G (2022) The next frontier in vaccine design: blending immune correlates of protection into rational vaccine design. Curr Opin Immunol 78:102234PubMedPubMedCentralCrossRef Britto C, Alter G (2022) The next frontier in vaccine design: blending immune correlates of protection into rational vaccine design. Curr Opin Immunol 78:102234PubMedPubMedCentralCrossRef
22.
go back to reference Brüssow H, Benitez O, Uribe F, Sidoti J, Rosa K, Cravioto A (1993) Rotavirus-inhibitory activity in serial milk samples from Mexican women and rotavirus infections in their children during their first year of life. J Clin Microbiol 31:593–597PubMedPubMedCentralCrossRef Brüssow H, Benitez O, Uribe F, Sidoti J, Rosa K, Cravioto A (1993) Rotavirus-inhibitory activity in serial milk samples from Mexican women and rotavirus infections in their children during their first year of life. J Clin Microbiol 31:593–597PubMedPubMedCentralCrossRef
23.
go back to reference Burke RM, Groom HC, Naleway AL, Katz EM, Salas B, Mattison CP, Donald J, Tsaknaridis L, Biggs C, Bowen MD, Tate JE, Parashar UD, Schmidt M, Hall AJ (2021) Rotavirus vaccine is effective against rotavirus gastroenteritis resulting in outpatient care: results from the medically attended acute gastroenteritis (MAAGE) study. Clin Infect Dis 72:2000–2005PubMedCrossRef Burke RM, Groom HC, Naleway AL, Katz EM, Salas B, Mattison CP, Donald J, Tsaknaridis L, Biggs C, Bowen MD, Tate JE, Parashar UD, Schmidt M, Hall AJ (2021) Rotavirus vaccine is effective against rotavirus gastroenteritis resulting in outpatient care: results from the medically attended acute gastroenteritis (MAAGE) study. Clin Infect Dis 72:2000–2005PubMedCrossRef
24.
go back to reference Burnett E, Jonesteller CL, Tate JE, Yen C, Parashar UD (2017) Global impact of rotavirus vaccination on childhood hospitalizations and mortality from diarrhea. J Infect Dis 215:1666–1672PubMedCrossRef Burnett E, Jonesteller CL, Tate JE, Yen C, Parashar UD (2017) Global impact of rotavirus vaccination on childhood hospitalizations and mortality from diarrhea. J Infect Dis 215:1666–1672PubMedCrossRef
25.
go back to reference Burnett E, Parashar UD, Tate JE (2020) Real-world effectiveness of rotavirus vaccines, 2006–19: a literature review and meta-analysis. Lancet Glob Health 8:e1195–e1202PubMedPubMedCentralCrossRef Burnett E, Parashar UD, Tate JE (2020) Real-world effectiveness of rotavirus vaccines, 2006–19: a literature review and meta-analysis. Lancet Glob Health 8:e1195–e1202PubMedPubMedCentralCrossRef
26.
go back to reference Burnett E, Parashar UD, Tate JE (2020) Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children <5 years old: 2006–2019. J Infect Dis 222:1731–1739PubMedCrossRef Burnett E, Parashar UD, Tate JE (2020) Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children <5 years old: 2006–2019. J Infect Dis 222:1731–1739PubMedCrossRef
27.
go back to reference Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB (1996) Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 272:104–107PubMedCrossRef Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB (1996) Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 272:104–107PubMedCrossRef
28.
go back to reference Caddy S, Papa G, Borodavka A, Desselberger U (2021) Rotavirus research: 2014–2020. Virus Res 304:198499PubMedCrossRef Caddy S, Papa G, Borodavka A, Desselberger U (2021) Rotavirus research: 2014–2020. Virus Res 304:198499PubMedCrossRef
29.
go back to reference Caddy SL, Vaysburd M, Wing M, Foss S, Andersen JT, O’Connell K, Mayes K, Higginson K, Iturriza-Gómara M, Desselberger U, Leo CJ (2020) Intracellular neutralisation of rotavirus by VP6-specific IgG. PLoS Pathog 16:e1008732PubMedPubMedCentralCrossRef Caddy SL, Vaysburd M, Wing M, Foss S, Andersen JT, O’Connell K, Mayes K, Higginson K, Iturriza-Gómara M, Desselberger U, Leo CJ (2020) Intracellular neutralisation of rotavirus by VP6-specific IgG. PLoS Pathog 16:e1008732PubMedPubMedCentralCrossRef
30.
go back to reference Cameron D, Bishop R, Veenstra A, Barnes G, Holmes I, Ruck B (1978) Pattern of shedding of two noncultivable viruses in stools of newborn babies. J Med Virol 2:7–13PubMedCrossRef Cameron D, Bishop R, Veenstra A, Barnes G, Holmes I, Ruck B (1978) Pattern of shedding of two noncultivable viruses in stools of newborn babies. J Med Virol 2:7–13PubMedCrossRef
32.
go back to reference Chan J, Nirwati H, Triasih R, Bogdanovic-Sakran N, Soenarto Y, Hakimi M, Duke T, Buttery JP, Bines JE, Bishop RF (2011) Maternal antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countries? Vaccine 29:1242–1247PubMedCrossRef Chan J, Nirwati H, Triasih R, Bogdanovic-Sakran N, Soenarto Y, Hakimi M, Duke T, Buttery JP, Bines JE, Bishop RF (2011) Maternal antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countries? Vaccine 29:1242–1247PubMedCrossRef
33.
go back to reference Chen J, Grow S, Iturriza-Gómara M, Hausdorff WP, Fix A, Kirkwood CD (2022) The challenges and opportunities of next-generation rotavirus vaccines: summary of an expert meeting with vaccine developers. Viruses 14:2565PubMedPubMedCentralCrossRef Chen J, Grow S, Iturriza-Gómara M, Hausdorff WP, Fix A, Kirkwood CD (2022) The challenges and opportunities of next-generation rotavirus vaccines: summary of an expert meeting with vaccine developers. Viruses 14:2565PubMedPubMedCentralCrossRef
34.
go back to reference Chen MY, Kirkwood CD, Bines J, Cowley D, Pavlic D, Lee KJ, Orsini F, Watts E, Barnes G, Danchin M (2017) Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand. Hum Vaccin Immunother 13:1126–1135PubMedPubMedCentralCrossRef Chen MY, Kirkwood CD, Bines J, Cowley D, Pavlic D, Lee KJ, Orsini F, Watts E, Barnes G, Danchin M (2017) Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand. Hum Vaccin Immunother 13:1126–1135PubMedPubMedCentralCrossRef
35.
go back to reference Chen S-Y, Tsai C-N, Lee Y-S, Lin C-Y, Huang K-Y, Chao H-C, Lai M-W, Chiu C-H (2017) Intestinal microbiome in children with severe and complicated acute viral gastroenteritis. Sci Rep 7:1–7 Chen S-Y, Tsai C-N, Lee Y-S, Lin C-Y, Huang K-Y, Chao H-C, Lai M-W, Chiu C-H (2017) Intestinal microbiome in children with severe and complicated acute viral gastroenteritis. Sci Rep 7:1–7
36.
go back to reference Chepngeno J, Amimo JO, Michael H, Raev SA, Jung K, Lee MV, Damtie D, Omwando A, Vlasova AN, Saif LJ (2023) Vitamin A deficiency and vitamin A supplementation affect innate and T cell immune responses to rotavirus A infection in a conventional sow model. Front Immunol 14:1188757PubMedPubMedCentralCrossRef Chepngeno J, Amimo JO, Michael H, Raev SA, Jung K, Lee MV, Damtie D, Omwando A, Vlasova AN, Saif LJ (2023) Vitamin A deficiency and vitamin A supplementation affect innate and T cell immune responses to rotavirus A infection in a conventional sow model. Front Immunol 14:1188757PubMedPubMedCentralCrossRef
37.
go back to reference Cheuvart B, Neuzil KM, Steele AD, Cunliffe N, Madhi SA, Karkada N, Han HH, Vinals C (2014) Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine. Hum Vaccin Immunother 10:505–511PubMedCrossRef Cheuvart B, Neuzil KM, Steele AD, Cunliffe N, Madhi SA, Karkada N, Han HH, Vinals C (2014) Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine. Hum Vaccin Immunother 10:505–511PubMedCrossRef
38.
go back to reference Chiba S, Nakata S, Urasawa T, Urasawa S, Yokoyama T, Morita Y, Taniguchi K, Nakao T (1986) Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet 328:417–421CrossRef Chiba S, Nakata S, Urasawa T, Urasawa S, Yokoyama T, Morita Y, Taniguchi K, Nakao T (1986) Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet 328:417–421CrossRef
39.
go back to reference Chiba S, Nakata S, Ukae S, Adachi N (1993) Virological and serological aspects of immune resistance to rotavirus gastroenteritis. Clin Infect Dis 16:S117–S121PubMedCrossRef Chiba S, Nakata S, Ukae S, Adachi N (1993) Virological and serological aspects of immune resistance to rotavirus gastroenteritis. Clin Infect Dis 16:S117–S121PubMedCrossRef
40.
go back to reference Chilengi R, Simuyandi M, Beach L, Mwila K, Becker-Dreps S, Emperador DM, Velasquez DE, Bosomprah S, Jiang B (2016) Association of maternal immunity with rotavirus vaccine immunogenicity in Zambian infants. PLoS ONE 11:e0150100PubMedPubMedCentralCrossRef Chilengi R, Simuyandi M, Beach L, Mwila K, Becker-Dreps S, Emperador DM, Velasquez DE, Bosomprah S, Jiang B (2016) Association of maternal immunity with rotavirus vaccine immunogenicity in Zambian infants. PLoS ONE 11:e0150100PubMedPubMedCentralCrossRef
41.
go back to reference Chilengi R, Mwila-Kazimbaya K, Chirwa M, Sukwa N, Chipeta C, Velu RM, Katanekwa N, Babji S, Kang G, McNeal MM, Meyer N, Gompana G, Hazra S, Tang Y, Flores J, Bhat N, Rathi N (2021) Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC® and ROTAVAC 5D® in Zambian infants. Vaccine 39:3633–3640PubMedPubMedCentralCrossRef Chilengi R, Mwila-Kazimbaya K, Chirwa M, Sukwa N, Chipeta C, Velu RM, Katanekwa N, Babji S, Kang G, McNeal MM, Meyer N, Gompana G, Hazra S, Tang Y, Flores J, Bhat N, Rathi N (2021) Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC® and ROTAVAC 5D® in Zambian infants. Vaccine 39:3633–3640PubMedPubMedCentralCrossRef
42.
go back to reference Choi AH, McNeal MM, Basu M, Flint JA, Stone SC, Clements JD, Bean JA, Poe SA, VanCott JL, Ward RL (2002) Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses. Vaccine 20:3310–3321PubMedCrossRef Choi AH, McNeal MM, Basu M, Flint JA, Stone SC, Clements JD, Bean JA, Poe SA, VanCott JL, Ward RL (2002) Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses. Vaccine 20:3310–3321PubMedCrossRef
43.
go back to reference Clark HF, Bernstein DI, Dennehy PH, Offit P, Pichichero M, Treanor J, Ward RL, Krah DL, Shaw A, Dallas MJ (2004) Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 144:184–190PubMedCrossRef Clark HF, Bernstein DI, Dennehy PH, Offit P, Pichichero M, Treanor J, Ward RL, Krah DL, Shaw A, Dallas MJ (2004) Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 144:184–190PubMedCrossRef
44.
go back to reference Clarke E, Desselberger U (2015) Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Mucosal Immunol 8:1–17PubMedCrossRef Clarke E, Desselberger U (2015) Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Mucosal Immunol 8:1–17PubMedCrossRef
45.
go back to reference Clemens J, Rao M, Ahmed F, Ward R, Huda S, Chakraborty J, Yunus M, Khan M, Ali M, Kay B (1993) Breast-feeding and the risk of life-threatening rotavirus diarrhea: prevention or postponement? Pediatrics 92:680–685PubMedCrossRef Clemens J, Rao M, Ahmed F, Ward R, Huda S, Chakraborty J, Yunus M, Khan M, Ali M, Kay B (1993) Breast-feeding and the risk of life-threatening rotavirus diarrhea: prevention or postponement? Pediatrics 92:680–685PubMedCrossRef
46.
go back to reference Clemens JD, Ward RL, Rao MR, Sack DA, Knowlton DR, van Loon FP, Huda S, McNeal M, Ahmed F, Schiff G (1992) Seroepidemiologic evaluation of antibodies to rotavirus as correlates of the risk of clinically significant rotavirus diarrhea in rural Bangladesh. J Infect Dis 165:161–165PubMedCrossRef Clemens JD, Ward RL, Rao MR, Sack DA, Knowlton DR, van Loon FP, Huda S, McNeal M, Ahmed F, Schiff G (1992) Seroepidemiologic evaluation of antibodies to rotavirus as correlates of the risk of clinically significant rotavirus diarrhea in rural Bangladesh. J Infect Dis 165:161–165PubMedCrossRef
47.
48.
go back to reference Conner ME, Crawford S, Barone C, O’Neal C, Zhou Y-J, Fernandez F, Parwani A, Saif L, Cohen J, Estes M (1996) Rotavirus subunit vaccines. Viral gastroenteritis. Springer, Vienna, pp 199–206CrossRef Conner ME, Crawford S, Barone C, O’Neal C, Zhou Y-J, Fernandez F, Parwani A, Saif L, Cohen J, Estes M (1996) Rotavirus subunit vaccines. Viral gastroenteritis. Springer, Vienna, pp 199–206CrossRef
49.
go back to reference Cowley D, Pavlic D, Bogdanovic-Sakran N, Boniface K, Kirkwood CD, Bines JE (2018) Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine. Hum Vaccin Immunother 14:2082–2087PubMedPubMedCentralCrossRef Cowley D, Pavlic D, Bogdanovic-Sakran N, Boniface K, Kirkwood CD, Bines JE (2018) Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine. Hum Vaccin Immunother 14:2082–2087PubMedPubMedCentralCrossRef
50.
go back to reference Crawford SE, Labbe M, Cohen J, Burroughs MH, Zhou Y-J, Estes MK (1994) Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol 68:5945–5952PubMedPubMedCentralCrossRef Crawford SE, Labbe M, Cohen J, Burroughs MH, Zhou Y-J, Estes MK (1994) Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol 68:5945–5952PubMedPubMedCentralCrossRef
51.
go back to reference Crawford SE, Estes MK, Ciarlet M, Barone C, O’Neal CM, Cohen J, Conner ME (1999) Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol 73:4813–4822PubMedPubMedCentralCrossRef Crawford SE, Estes MK, Ciarlet M, Barone C, O’Neal CM, Cohen J, Conner ME (1999) Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol 73:4813–4822PubMedPubMedCentralCrossRef
52.
go back to reference Crawford SE, Ramani S, Tate JE, Parashar UD, Svensson L, Hagbom M, Franco MA, Greenberg HB, O’Ryan M, Kang G (2017) Rotavirus infection. Nat Rev Dis Prim 3:1–16 Crawford SE, Ramani S, Tate JE, Parashar UD, Svensson L, Hagbom M, Franco MA, Greenberg HB, O’Ryan M, Kang G (2017) Rotavirus infection. Nat Rev Dis Prim 3:1–16
53.
go back to reference Cunliffe NA, Witte D, Ngwira BM, Todd S, Bostock NJ, Turner AM, Chimpeni P, Victor JC, Steele AD, Bouckenooghe A (2012) Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine 30:A36–A43PubMedPubMedCentralCrossRef Cunliffe NA, Witte D, Ngwira BM, Todd S, Bostock NJ, Turner AM, Chimpeni P, Victor JC, Steele AD, Bouckenooghe A (2012) Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine 30:A36–A43PubMedPubMedCentralCrossRef
54.
go back to reference Danchin MH, Bines JE, Watts E, Cowley D, Pavlic D, Lee KJ, Huque H, Kirkwood C, Nirwati H, At thobari J, Dewi Satria C, Soenarto Y, Oktaria V (2020) Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia. Vaccine 38:3235–3242PubMedCrossRef Danchin MH, Bines JE, Watts E, Cowley D, Pavlic D, Lee KJ, Huque H, Kirkwood C, Nirwati H, At thobari J, Dewi Satria C, Soenarto Y, Oktaria V (2020) Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia. Vaccine 38:3235–3242PubMedCrossRef
55.
go back to reference Desselberger U, Huppertz H-I (2011) Immune responses to rotavirus infection and vaccination and associated correlates of protection. J Infect Dis 203:188–195PubMedPubMedCentralCrossRef Desselberger U, Huppertz H-I (2011) Immune responses to rotavirus infection and vaccination and associated correlates of protection. J Infect Dis 203:188–195PubMedPubMedCentralCrossRef
57.
go back to reference Desselberger U (2018) The mammalian intestinal microbiome: composition, interaction with the immune system, significance for vaccine efficacy, and potential for disease therapy. Pathogens 7:57PubMedPubMedCentralCrossRef Desselberger U (2018) The mammalian intestinal microbiome: composition, interaction with the immune system, significance for vaccine efficacy, and potential for disease therapy. Pathogens 7:57PubMedPubMedCentralCrossRef
58.
go back to reference Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P, Plotkin SA (2021) Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39:4423–4428PubMedPubMedCentralCrossRef Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P, Plotkin SA (2021) Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39:4423–4428PubMedPubMedCentralCrossRef
59.
go back to reference Ella R, Babji S, Ciarlet M, Blackwelder WC, Vadrevu KM (2019) A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants. Vaccine 37:4407–4413PubMedCrossRef Ella R, Babji S, Ciarlet M, Blackwelder WC, Vadrevu KM (2019) A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants. Vaccine 37:4407–4413PubMedCrossRef
60.
go back to reference Enya Y, Hiramatsu H, Ihira M, Suzuki R, Higashimoto Y, Funato Y, Kozawa K, Miura H, Miyata M, Kawamura Y (2023) Similarities in rotavirus vaccine viral shedding and immune responses in pairs of twins. Fujita Med J 9:253–258PubMedPubMedCentral Enya Y, Hiramatsu H, Ihira M, Suzuki R, Higashimoto Y, Funato Y, Kozawa K, Miura H, Miyata M, Kawamura Y (2023) Similarities in rotavirus vaccine viral shedding and immune responses in pairs of twins. Fujita Med J 9:253–258PubMedPubMedCentral
61.
go back to reference Espinoza F, Paniagua M, Hallander H, Svensson L, Strannegård Ö (1997) Rotavirus infections in young Nicaraguan children. Pediatr Infect Dis J 16:564–571PubMedCrossRef Espinoza F, Paniagua M, Hallander H, Svensson L, Strannegård Ö (1997) Rotavirus infections in young Nicaraguan children. Pediatr Infect Dis J 16:564–571PubMedCrossRef
63.
go back to reference Feng N, Lawton JA, Gilbert J, Kuklin N, Vo P, Prasad BV, Greenberg HB (2002) Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. J Clin Investig 109:1203–1213PubMedPubMedCentralCrossRef Feng N, Lawton JA, Gilbert J, Kuklin N, Vo P, Prasad BV, Greenberg HB (2002) Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. J Clin Investig 109:1203–1213PubMedPubMedCentralCrossRef
64.
go back to reference Fischer TK, Valentiner-Branth P, Steinsland H, Perch M, Santos G, Aaby P, Mølbak K, Sommerfelt H (2002) Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west Africa. J Infect Dis 186:593–597PubMedCrossRef Fischer TK, Valentiner-Branth P, Steinsland H, Perch M, Santos G, Aaby P, Mølbak K, Sommerfelt H (2002) Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west Africa. J Infect Dis 186:593–597PubMedCrossRef
65.
go back to reference Franco MA, Angel J, Greenberg HB (2006) Immunity and correlates of protection for rotavirus vaccines. Vaccine 24:2718–2731PubMedCrossRef Franco MA, Angel J, Greenberg HB (2006) Immunity and correlates of protection for rotavirus vaccines. Vaccine 24:2718–2731PubMedCrossRef
66.
go back to reference Gil MT, de Souza CO, Asensi M, Buesa J (2000) Homotypic protection against rotavirus-induced diarrhea in infant mice breast-fed by dams immunized with the recombinant VP8* subunit of the VP4 capsid protein. Viral Immunol 13:187–200PubMedCrossRef Gil MT, de Souza CO, Asensi M, Buesa J (2000) Homotypic protection against rotavirus-induced diarrhea in infant mice breast-fed by dams immunized with the recombinant VP8* subunit of the VP4 capsid protein. Viral Immunol 13:187–200PubMedCrossRef
67.
go back to reference Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L (2022) Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375:43–50PubMedCrossRef Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L (2022) Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375:43–50PubMedCrossRef
68.
go back to reference Gladstone BP, Ramani S, Mukhopadhya I, Muliyil J, Sarkar R, Rehman AM, Jaffar S, Gomara MI, Gray JJ, Brown DW (2011) Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 365:337–346PubMedPubMedCentralCrossRef Gladstone BP, Ramani S, Mukhopadhya I, Muliyil J, Sarkar R, Rehman AM, Jaffar S, Gomara MI, Gray JJ, Brown DW (2011) Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 365:337–346PubMedPubMedCentralCrossRef
69.
go back to reference Glass RI, Tate JE, Jiang B, Parashar U (2021) The rotavirus vaccine story: from discovery to the eventual control of rotavirus disease. J Infect Dis 224:S331–S342PubMedPubMedCentralCrossRef Glass RI, Tate JE, Jiang B, Parashar U (2021) The rotavirus vaccine story: from discovery to the eventual control of rotavirus disease. J Infect Dis 224:S331–S342PubMedPubMedCentralCrossRef
70.
go back to reference Goldblatt D, Alter G, Crotty S, Plotkin SA (2022) Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol Rev 310:6–26PubMedCrossRef Goldblatt D, Alter G, Crotty S, Plotkin SA (2022) Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol Rev 310:6–26PubMedCrossRef
71.
go back to reference Gonzalez A, Nguyen T, Azevedo M, Jeong K, Agarib F, Iosef C, Chang K, Lovgren-Bengtsson K, Morein B, Saif LJ (2004) Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM. Clin Exp Immunol 135:361–372PubMedPubMedCentralCrossRef Gonzalez A, Nguyen T, Azevedo M, Jeong K, Agarib F, Iosef C, Chang K, Lovgren-Bengtsson K, Morein B, Saif LJ (2004) Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM. Clin Exp Immunol 135:361–372PubMedPubMedCentralCrossRef
72.
go back to reference Gonzalez AM, Jaimes MC, Cajiao I, Rojas OL, Cohen J, Pothier P, Kohli E, Butcher EC, Greenberg HB, Angel J (2003) Rotavirus-specific B cells induced by recent infection in adults and children predominantly express the intestinal homing receptor α4β7. Virology 305:93–105PubMedCrossRef Gonzalez AM, Jaimes MC, Cajiao I, Rojas OL, Cohen J, Pothier P, Kohli E, Butcher EC, Greenberg HB, Angel J (2003) Rotavirus-specific B cells induced by recent infection in adults and children predominantly express the intestinal homing receptor α4β7. Virology 305:93–105PubMedCrossRef
73.
go back to reference González R, Franco M, Sarmiento L, Romero M, Schael IP (2005) Serum IgA levels induced by rotavirus natural infection, but not following immunization with the RRV-TV vaccine (Rotashield), correlate with protection. J Med Virol 76:608–612PubMedCrossRef González R, Franco M, Sarmiento L, Romero M, Schael IP (2005) Serum IgA levels induced by rotavirus natural infection, but not following immunization with the RRV-TV vaccine (Rotashield), correlate with protection. J Med Virol 76:608–612PubMedCrossRef
74.
go back to reference Green K, Kapikian AZ (1992) Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers. J Virol 66:548–553PubMedPubMedCentralCrossRef Green K, Kapikian AZ (1992) Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers. J Virol 66:548–553PubMedPubMedCentralCrossRef
75.
go back to reference Green KY, Taniguchi K, Mackow ER, Kapikian AZ (1990) Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. J Infect Dis 161:667–679PubMedCrossRef Green KY, Taniguchi K, Mackow ER, Kapikian AZ (1990) Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. J Infect Dis 161:667–679PubMedCrossRef
76.
go back to reference Groome M, Fairlie L, Morrison J, Fix A, Koen A, Masenya M, Page N, Jose L, Madhi S, McNeal M (2018) Safety and immunogenicity of a parenteral P2-VP8 subunit rotavirus vaccine. In: International rotavirus symposium Minsk, Belarus Groome M, Fairlie L, Morrison J, Fix A, Koen A, Masenya M, Page N, Jose L, Madhi S, McNeal M (2018) Safety and immunogenicity of a parenteral P2-VP8 subunit rotavirus vaccine. In: International rotavirus symposium Minsk, Belarus
77.
go back to reference Groome MJ, Moon S-S, Velasquez D, Jones S, Koen A, Nv N, Jiang B, Parashar UD, Madhi SA (2014) Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. Bull World Health Organ 92:238–245PubMedPubMedCentralCrossRef Groome MJ, Moon S-S, Velasquez D, Jones S, Koen A, Nv N, Jiang B, Parashar UD, Madhi SA (2014) Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. Bull World Health Organ 92:238–245PubMedPubMedCentralCrossRef
78.
go back to reference Groome MJ, Koen A, Fix A, Page N, Jose L, Madhi SA, McNeal M, Dally L, Cho I, Power M (2017) Safety and immunogenicity of a parenteral P2-VP8-P [8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 17:843–853PubMedPubMedCentralCrossRef Groome MJ, Koen A, Fix A, Page N, Jose L, Madhi SA, McNeal M, Dally L, Cho I, Power M (2017) Safety and immunogenicity of a parenteral P2-VP8-P [8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 17:843–853PubMedPubMedCentralCrossRef
79.
go back to reference Groome MJ, Fairlie L, Morrison J, Fix A, Koen A, Masenya M, Jose L, Madhi SA, Page N, McNeal M (2020) Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 20:851–863PubMedPubMedCentralCrossRef Groome MJ, Fairlie L, Morrison J, Fix A, Koen A, Masenya M, Jose L, Madhi SA, Page N, McNeal M (2020) Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 20:851–863PubMedPubMedCentralCrossRef
80.
81.
go back to reference Harris VC, Haak BW, Handley SA, Jiang B, Velasquez DE, Hykes BL, Droit L, Berbers GAM, Kemper EM, van Leeuwen EMM, Boele van Hensbroek M, Wiersinga WJ (2018) Effect of antibiotic-mediated microbiome modulation on rotavirus vaccine immunogenicity: a human, randomized-control proof-of-concept trial. Cell Host Microbe 24:197-207.e194PubMedCrossRef Harris VC, Haak BW, Handley SA, Jiang B, Velasquez DE, Hykes BL, Droit L, Berbers GAM, Kemper EM, van Leeuwen EMM, Boele van Hensbroek M, Wiersinga WJ (2018) Effect of antibiotic-mediated microbiome modulation on rotavirus vaccine immunogenicity: a human, randomized-control proof-of-concept trial. Cell Host Microbe 24:197-207.e194PubMedCrossRef
82.
go back to reference Henschke N, Bergman H, Hungerford D, Cunliffe N, Grais R, Kang G, Parashar U, Wang S, Neuzil K (2022) The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality. Vaccine 40:1707–1711PubMedPubMedCentralCrossRef Henschke N, Bergman H, Hungerford D, Cunliffe N, Grais R, Kang G, Parashar U, Wang S, Neuzil K (2022) The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality. Vaccine 40:1707–1711PubMedPubMedCentralCrossRef
83.
go back to reference Hensley C, Nyblade C, Zhou P, Parreño V, Ramesh A, Frazier A, Frazier M, Garrison S, Fantasia-Davis A, Cai R (2023) Combined live oral priming and intramuscular boosting regimen with Rotarix® and a nanoparticle-based trivalent rotavirus vaccine evaluated in gnotobiotic pig models of G4P [6] and G1P [8] human rotavirus infection. Vaccines 11:927PubMedPubMedCentralCrossRef Hensley C, Nyblade C, Zhou P, Parreño V, Ramesh A, Frazier A, Frazier M, Garrison S, Fantasia-Davis A, Cai R (2023) Combined live oral priming and intramuscular boosting regimen with Rotarix® and a nanoparticle-based trivalent rotavirus vaccine evaluated in gnotobiotic pig models of G4P [6] and G1P [8] human rotavirus infection. Vaccines 11:927PubMedPubMedCentralCrossRef
84.
go back to reference Hjelt K, Paerregaard A, Nielsen OH, Krasilnikoff PA, Grauballe PC (1987) Protective effect of preexisting rotavirus-specific immunoglobulin A against naturally acquired rotavirus infection in children. J Med Virol 21:39–47PubMedCrossRef Hjelt K, Paerregaard A, Nielsen OH, Krasilnikoff PA, Grauballe PC (1987) Protective effect of preexisting rotavirus-specific immunoglobulin A against naturally acquired rotavirus infection in children. J Med Virol 21:39–47PubMedCrossRef
85.
go back to reference Holmgren J, Parashar UD, Plotkin S, Louis J, Ng S-P, Desauziers E, Picot V, Saadatian-Elahi M (2017) Correlates of protection for enteric vaccines. Vaccine 35:3355–3363PubMedCrossRef Holmgren J, Parashar UD, Plotkin S, Louis J, Ng S-P, Desauziers E, Picot V, Saadatian-Elahi M (2017) Correlates of protection for enteric vaccines. Vaccine 35:3355–3363PubMedCrossRef
86.
go back to reference Isanaka S, Langendorf C, McNeal MM, Meyer N, Plikaytis B, Garba S, Sayinzoga-Makombe N, Soumana I, Guindo O, Makarimi R (2021) Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: extended follow-up of a randomized controlled trial. PLoS Med 18:e1003655PubMedPubMedCentralCrossRef Isanaka S, Langendorf C, McNeal MM, Meyer N, Plikaytis B, Garba S, Sayinzoga-Makombe N, Soumana I, Guindo O, Makarimi R (2021) Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: extended follow-up of a randomized controlled trial. PLoS Med 18:e1003655PubMedPubMedCentralCrossRef
87.
go back to reference MaC J, Rojas OL, Kunkel EJ, Lazarus NH, Soler D, Butcher EC, Bass D, Angel J, Franco MA, Greenberg HB (2004) Maturation and trafficking markers on rotavirus-specific B cells during acute infection and convalescence in children. J Virol 78:10967–10976CrossRef MaC J, Rojas OL, Kunkel EJ, Lazarus NH, Soler D, Butcher EC, Bass D, Angel J, Franco MA, Greenberg HB (2004) Maturation and trafficking markers on rotavirus-specific B cells during acute infection and convalescence in children. J Virol 78:10967–10976CrossRef
88.
go back to reference Jaimes MC, Rojas OL, González AM, Cajiao I, Charpilienne A, Pothier P, Kohli E, Greenberg HB, Franco MA, Angel J (2002) Frequencies of virus-specific CD4+ and CD8+ T lymphocytes secreting gamma interferon after acute natural rotavirus infection in children and adults. J Virol 76:4741–4749PubMedPubMedCentralCrossRef Jaimes MC, Rojas OL, González AM, Cajiao I, Charpilienne A, Pothier P, Kohli E, Greenberg HB, Franco MA, Angel J (2002) Frequencies of virus-specific CD4+ and CD8+ T lymphocytes secreting gamma interferon after acute natural rotavirus infection in children and adults. J Virol 76:4741–4749PubMedPubMedCentralCrossRef
89.
go back to reference Jayashree S, Bhan M, Kumar R, Bhandari N, Sazawal S (1988) Protection against neonatal rotavirus infection by breast milk antibodies and trypsin inhibitors. J Med Virol 26:333–338PubMedCrossRef Jayashree S, Bhan M, Kumar R, Bhandari N, Sazawal S (1988) Protection against neonatal rotavirus infection by breast milk antibodies and trypsin inhibitors. J Med Virol 26:333–338PubMedCrossRef
90.
go back to reference Jiang B, Estes MK, Barone C, Barniak V, O’Neal CM, Ottaiano A, Madore HP, Conner ME (1999) Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 17:1005–1013PubMedCrossRef Jiang B, Estes MK, Barone C, Barniak V, O’Neal CM, Ottaiano A, Madore HP, Conner ME (1999) Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 17:1005–1013PubMedCrossRef
91.
go back to reference Jonesteller CL, Burnett E, Yen C, Tate JE, Parashar UD (2017) Effectiveness of rotavirus vaccination: a systematic review of the first decade of global postlicensure data, 2006–2016. Clin Infect Dis 65:840–850PubMedCrossRef Jonesteller CL, Burnett E, Yen C, Tate JE, Parashar UD (2017) Effectiveness of rotavirus vaccination: a systematic review of the first decade of global postlicensure data, 2006–2016. Clin Infect Dis 65:840–850PubMedCrossRef
92.
go back to reference Kandasamy S, Chattha KS, Vlasova AN, Rajashekara G, Saif LJ (2014) Lactobacilli and Bifidobacteria enhance mucosal B cell responses and differentially modulate systemic antibody responses to an oral human rotavirus vaccine in a neonatal gnotobiotic pig disease model. Gut microbes 5:639–651PubMedPubMedCentralCrossRef Kandasamy S, Chattha KS, Vlasova AN, Rajashekara G, Saif LJ (2014) Lactobacilli and Bifidobacteria enhance mucosal B cell responses and differentially modulate systemic antibody responses to an oral human rotavirus vaccine in a neonatal gnotobiotic pig disease model. Gut microbes 5:639–651PubMedPubMedCentralCrossRef
93.
go back to reference Kapikian A, Wyatt R, Levine M, Yolken R, VanKirk D, Dolin R, Greenberg H, Chanock R (1983) Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance. J Infect Dis 147:95–106PubMedCrossRef Kapikian A, Wyatt R, Levine M, Yolken R, VanKirk D, Dolin R, Greenberg H, Chanock R (1983) Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance. J Infect Dis 147:95–106PubMedCrossRef
94.
go back to reference Kavanagh O, Zeng X-L, Ramani S, Mukhopadhya I, Crawford SE, Kang G, Estes MK (2013) A time-resolved immunoassay to measure serum antibodies to the rotavirus VP6 capsid protein. J Virol Methods 189:228–231PubMedPubMedCentralCrossRef Kavanagh O, Zeng X-L, Ramani S, Mukhopadhya I, Crawford SE, Kang G, Estes MK (2013) A time-resolved immunoassay to measure serum antibodies to the rotavirus VP6 capsid protein. J Virol Methods 189:228–231PubMedPubMedCentralCrossRef
95.
go back to reference Kawamura N, Tokoeda Y, Oshima M, Okahata H, Tsutsumi H, Van Doorn LJ, Muto H, Smolenov I, Suryakiran P, Han HH (2011) Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine 29:6335–6341PubMedCrossRef Kawamura N, Tokoeda Y, Oshima M, Okahata H, Tsutsumi H, Van Doorn LJ, Muto H, Smolenov I, Suryakiran P, Han HH (2011) Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine 29:6335–6341PubMedCrossRef
96.
go back to reference Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP (2021) Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27:1205–1211PubMedCrossRef Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP (2021) Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27:1205–1211PubMedCrossRef
97.
go back to reference Kim AH, Hogarty MP, Harris VC, Baldridge MT (2021) The complex interactions between rotavirus and the gut microbiota. Front Cell Infect Microbiol 10:586751PubMedPubMedCentralCrossRef Kim AH, Hogarty MP, Harris VC, Baldridge MT (2021) The complex interactions between rotavirus and the gut microbiota. Front Cell Infect Microbiol 10:586751PubMedPubMedCentralCrossRef
98.
go back to reference Kotloff KL (2017) The burden and etiology of diarrheal illness in developing countries. Pediatr Clin N Am 64:799–814CrossRef Kotloff KL (2017) The burden and etiology of diarrheal illness in developing countries. Pediatr Clin N Am 64:799–814CrossRef
99.
go back to reference Kulkarni PS, Desai S, Tewari T, Kawade A, Goyal N, Garg BS, Kumar D, Kanungo S, Kamat V, Kang G (2017) A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine 35:6228–6237PubMedPubMedCentralCrossRef Kulkarni PS, Desai S, Tewari T, Kawade A, Goyal N, Garg BS, Kumar D, Kanungo S, Kamat V, Kang G (2017) A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine 35:6228–6237PubMedPubMedCentralCrossRef
100.
go back to reference Kurokawa N, Robinson MK, Bernard C, Kawaguchi Y, Koujin Y, Koen A, Madhi S, Polasek TM, McNeal M, Dargis M (2021) Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. Vaccine 39:5513–5523PubMedCrossRef Kurokawa N, Robinson MK, Bernard C, Kawaguchi Y, Koujin Y, Koen A, Madhi S, Polasek TM, McNeal M, Dargis M (2021) Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. Vaccine 39:5513–5523PubMedCrossRef
101.
go back to reference Laban NM, Goodier MR, Bosomprah S, Simuyandi M, Chisenga C, Chilyabanyama ON, Chilengi R (2022) T-cell responses after rotavirus infection or vaccination in children: a systematic review. Viruses 14:459PubMedPubMedCentralCrossRef Laban NM, Goodier MR, Bosomprah S, Simuyandi M, Chisenga C, Chilyabanyama ON, Chilengi R (2022) T-cell responses after rotavirus infection or vaccination in children: a systematic review. Viruses 14:459PubMedPubMedCentralCrossRef
102.
go back to reference Lamberti LM, Ashraf S, Walker CLF, Black RE (2016) A systematic review of the effect of rotavirus vaccination on diarrhea outcomes among children younger than 5 years. Pediatr Infect Dis J 35:992–998PubMedCrossRef Lamberti LM, Ashraf S, Walker CLF, Black RE (2016) A systematic review of the effect of rotavirus vaccination on diarrhea outcomes among children younger than 5 years. Pediatr Infect Dis J 35:992–998PubMedCrossRef
103.
go back to reference Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE, Organization CHERGotWH, UNICEF (2013) Global causes of diarrheal disease mortality in children< 5 years of age: a systematic review. PLoS ONE 8:e72788PubMedPubMedCentralCrossRef Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE, Organization CHERGotWH, UNICEF (2013) Global causes of diarrheal disease mortality in children< 5 years of age: a systematic review. PLoS ONE 8:e72788PubMedPubMedCentralCrossRef
104.
go back to reference Langel S, Steppe J, Chang J, Travieso T, Webster H, Otero C, Williamson L, Crowe J, Greenberg H, Wu H, Hornik C, Mansouri K, Edwards R, Stalls V, Acharya P, Blasi M, Permar S (2021) Protective transfer: maternal passive immunization with a rotavirus-neutralizing dimeric IgA protects against rotavirus disease in suckling neonates. bioRxiv: 2021.2009.2021.461116 Langel S, Steppe J, Chang J, Travieso T, Webster H, Otero C, Williamson L, Crowe J, Greenberg H, Wu H, Hornik C, Mansouri K, Edwards R, Stalls V, Acharya P, Blasi M, Permar S (2021) Protective transfer: maternal passive immunization with a rotavirus-neutralizing dimeric IgA protects against rotavirus disease in suckling neonates. bioRxiv: 2021.2009.2021.461116
105.
go back to reference Lappalainen S, Pastor AR, Tamminen K, López-Guerrero V, Esquivel-Guadarrama F, Palomares LA, Vesikari T, Blazevic V (2014) Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo. Hum Vaccin Immunother 10:2039–2047PubMedPubMedCentralCrossRef Lappalainen S, Pastor AR, Tamminen K, López-Guerrero V, Esquivel-Guadarrama F, Palomares LA, Vesikari T, Blazevic V (2014) Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo. Hum Vaccin Immunother 10:2039–2047PubMedPubMedCentralCrossRef
106.
go back to reference Lappalainen S, Blazevic V, Malm M, Vesikari T (2017) Rotavirus vaccination and infection induce VP6-specific IgA responses. J Med Virol 89:239–245PubMedCrossRef Lappalainen S, Blazevic V, Malm M, Vesikari T (2017) Rotavirus vaccination and infection induce VP6-specific IgA responses. J Med Virol 89:239–245PubMedCrossRef
107.
go back to reference Latifi T, Jalilvand S, Golsaz-Shirazi F, Arashkia A, Kachooei A, Afchangi A, Zafarian S, Roohvand F, Shoja Z (2023) Characterization and immunogenicity of a novel chimeric hepatitis B core-virus like particles (cVLPs) carrying rotavirus VP8* protein in mice model. Virology 588:109903PubMedCrossRef Latifi T, Jalilvand S, Golsaz-Shirazi F, Arashkia A, Kachooei A, Afchangi A, Zafarian S, Roohvand F, Shoja Z (2023) Characterization and immunogenicity of a novel chimeric hepatitis B core-virus like particles (cVLPs) carrying rotavirus VP8* protein in mice model. Virology 588:109903PubMedCrossRef
108.
go back to reference Lau Y-L, Nelson EAS, Poon K-H, Chan PK, Chiu S, Sung R, Leung CW, Ng D, Ma YM, Chan D (2013) Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine 31:2253–2259PubMedCrossRef Lau Y-L, Nelson EAS, Poon K-H, Chan PK, Chiu S, Sung R, Leung CW, Ng D, Ma YM, Chan D (2013) Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine 31:2253–2259PubMedCrossRef
109.
go back to reference Lazarus RP, John J, Shanmugasundaram E, Rajan AK, Thiagarajan S, Giri S, Babji S, Sarkar R, Kaliappan PS, Venugopal S (2018) The effect of probiotics and zinc supplementation on the immune response to oral rotavirus vaccine: a randomized, factorial design, placebo-controlled study among Indian infants. Vaccine 36:273–279PubMedCrossRef Lazarus RP, John J, Shanmugasundaram E, Rajan AK, Thiagarajan S, Giri S, Babji S, Sarkar R, Kaliappan PS, Venugopal S (2018) The effect of probiotics and zinc supplementation on the immune response to oral rotavirus vaccine: a randomized, factorial design, placebo-controlled study among Indian infants. Vaccine 36:273–279PubMedCrossRef
110.
go back to reference Lee B, Carmolli M, Dickson DM, Colgate ER, Diehl SA, Uddin MI, Islam S, Hossain M, Rafique TA, Bhuiyan TR, Alam M, Nayak U, Mychaleckyj JC, McNeal MM, Petri WA, Qadri F, Haque R, Kirkpatrick BD (2018) Rotavirus-specific immunoglobulin A responses are impaired and serve as a suboptimal correlate of protection among infants in Bangladesh. Clin Infect Dis 67:186–192PubMedPubMedCentralCrossRef Lee B, Carmolli M, Dickson DM, Colgate ER, Diehl SA, Uddin MI, Islam S, Hossain M, Rafique TA, Bhuiyan TR, Alam M, Nayak U, Mychaleckyj JC, McNeal MM, Petri WA, Qadri F, Haque R, Kirkpatrick BD (2018) Rotavirus-specific immunoglobulin A responses are impaired and serve as a suboptimal correlate of protection among infants in Bangladesh. Clin Infect Dis 67:186–192PubMedPubMedCentralCrossRef
111.
go back to reference Lee B (2021) Update on rotavirus vaccine underperformance in low-to middle-income countries and next-generation vaccines. Hum Vaccin Immunother 17:1787–1802PubMedCrossRef Lee B (2021) Update on rotavirus vaccine underperformance in low-to middle-income countries and next-generation vaccines. Hum Vaccin Immunother 17:1787–1802PubMedCrossRef
112.
go back to reference Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S, Bouckenooghe A, Neuzil KM, Steele AD (2012) Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine 30:A44–A51PubMedCrossRef Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S, Bouckenooghe A, Neuzil KM, Steele AD (2012) Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine 30:A44–A51PubMedCrossRef
113.
go back to reference Maffey L, Vega CG, Miño S, Garaicoechea L, Parreño V (2016) Anti-VP6 VHH: an experimental treatment for rotavirus A-associated disease. PLoS ONE 11:e0162351PubMedPubMedCentralCrossRef Maffey L, Vega CG, Miño S, Garaicoechea L, Parreño V (2016) Anti-VP6 VHH: an experimental treatment for rotavirus A-associated disease. PLoS ONE 11:e0162351PubMedPubMedCentralCrossRef
114.
go back to reference Malamba-Banda C, Mhango C, Benedicto-Matambo P, Mandolo JJ, Chinyama E, Kumwenda O, Barnes KG, Cunliffe NA, Iturriza-Gomara M, Jambo KC (2023) Acute rotavirus infection is associated with the induction of circulating memory CD4+ T cell subsets. Sci Rep 13:9001PubMedPubMedCentralCrossRef Malamba-Banda C, Mhango C, Benedicto-Matambo P, Mandolo JJ, Chinyama E, Kumwenda O, Barnes KG, Cunliffe NA, Iturriza-Gomara M, Jambo KC (2023) Acute rotavirus infection is associated with the induction of circulating memory CD4+ T cell subsets. Sci Rep 13:9001PubMedPubMedCentralCrossRef
115.
go back to reference Malm M, Hyöty H, Knip M, Vesikari T, Blazevic V (2019) Development of T cell immunity to norovirus and rotavirus in children under five years of age. Sci Rep 9:1–9CrossRef Malm M, Hyöty H, Knip M, Vesikari T, Blazevic V (2019) Development of T cell immunity to norovirus and rotavirus in children under five years of age. Sci Rep 9:1–9CrossRef
116.
go back to reference Matson DO, O’Ryan ML, Herrera I, Pickering LK, Estes MK (1993) Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis 167:577–583PubMedCrossRef Matson DO, O’Ryan ML, Herrera I, Pickering LK, Estes MK (1993) Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis 167:577–583PubMedCrossRef
117.
go back to reference McAdams D, Estrada M, Holland D, Singh J, Sawant N, Hickey JM, Kumar P, Plikaytis B, Joshi SB, Volkin DB (2022) Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency. Vaccine 40:5069–5078PubMedPubMedCentralCrossRef McAdams D, Estrada M, Holland D, Singh J, Sawant N, Hickey JM, Kumar P, Plikaytis B, Joshi SB, Volkin DB (2022) Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency. Vaccine 40:5069–5078PubMedPubMedCentralCrossRef
118.
go back to reference McNeal MM, Rae MN, Ward RL (1997) Evidence that resolution of rotavirus infection in mice is due to both CD4 and CD8 cell-dependent activities. J Virol 71:8735–8742PubMedPubMedCentralCrossRef McNeal MM, Rae MN, Ward RL (1997) Evidence that resolution of rotavirus infection in mice is due to both CD4 and CD8 cell-dependent activities. J Virol 71:8735–8742PubMedPubMedCentralCrossRef
119.
go back to reference McNeal MM, VanCott JL, Choi AH, Basu M, Flint JA, Stone SC, Clements JD, Ward RL (2002) CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G). J Virol 76:560–568PubMedPubMedCentralCrossRef McNeal MM, VanCott JL, Choi AH, Basu M, Flint JA, Stone SC, Clements JD, Ward RL (2002) CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G). J Virol 76:560–568PubMedPubMedCentralCrossRef
120.
go back to reference Metrics IfH, Evaluation (2017) Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016 (GBD 2016) results. Institute for Health Metrics and Evaluation, Seattle Metrics IfH, Evaluation (2017) Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016 (GBD 2016) results. Institute for Health Metrics and Evaluation, Seattle
121.
go back to reference Middleton BF, Danchin M, Cunliffe NA, Jones MA, Boniface K, Kirkwood CD, Gallagher S, Kirkham L-A, Granland C, McNeal M (2023) Histo-blood group antigen profile of Australian Aboriginal children and seropositivity following oral rotavirus vaccination. Vaccine 41:3579–3583PubMedCrossRef Middleton BF, Danchin M, Cunliffe NA, Jones MA, Boniface K, Kirkwood CD, Gallagher S, Kirkham L-A, Granland C, McNeal M (2023) Histo-blood group antigen profile of Australian Aboriginal children and seropositivity following oral rotavirus vaccination. Vaccine 41:3579–3583PubMedCrossRef
122.
go back to reference Mo Z, Ma X, Luo P, Mo Y, Kaplan SS, Shou Q, Zheng M, Hille DA, Arnold BA, Liao X (2019) Immunogenicity of pentavalent rotavirus vaccine in Chinese infants. Vaccine 37:1836–1843PubMedCrossRef Mo Z, Ma X, Luo P, Mo Y, Kaplan SS, Shou Q, Zheng M, Hille DA, Arnold BA, Liao X (2019) Immunogenicity of pentavalent rotavirus vaccine in Chinese infants. Vaccine 37:1836–1843PubMedCrossRef
123.
go back to reference Moon S-S, Wang Y, Shane AL, Nguyen T, Ray P, Dennehy P, Baek LJ, Parashar U, Glass RI, Jiang B (2010) Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J 29:919PubMedPubMedCentralCrossRef Moon S-S, Wang Y, Shane AL, Nguyen T, Ray P, Dennehy P, Baek LJ, Parashar U, Glass RI, Jiang B (2010) Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J 29:919PubMedPubMedCentralCrossRef
124.
go back to reference Moon S-S, Tate JE, Ray P, Dennehy PH, Archary D, Coutsoudis A, Bland R, Newell M-L, Glass RI, Parashar U (2013) Differential profiles and inhibitory effect on rotavirus vaccines of nonantibody components in breast milk from mothers in developing and developed countries. Pediatr Infect Dis J 32:863PubMedPubMedCentralCrossRef Moon S-S, Tate JE, Ray P, Dennehy PH, Archary D, Coutsoudis A, Bland R, Newell M-L, Glass RI, Parashar U (2013) Differential profiles and inhibitory effect on rotavirus vaccines of nonantibody components in breast milk from mothers in developing and developed countries. Pediatr Infect Dis J 32:863PubMedPubMedCentralCrossRef
125.
go back to reference Nair N, Feng N, Blum LK, Sanyal M, Ding S, Jiang B, Sen A, Morton JM, He X-S, Robinson WH, Greenberg HB (2017) VP4- and VP7-specific antibodies mediate heterotypic immunity to rotavirus in humans. Sci Transl Med 9:eaam5434PubMedPubMedCentralCrossRef Nair N, Feng N, Blum LK, Sanyal M, Ding S, Jiang B, Sen A, Morton JM, He X-S, Robinson WH, Greenberg HB (2017) VP4- and VP7-specific antibodies mediate heterotypic immunity to rotavirus in humans. Sci Transl Med 9:eaam5434PubMedPubMedCentralCrossRef
126.
go back to reference Nordgren J, Sharma S, Bucardo F, Nasir W, Gunaydin G, Ouermi D, Nitiema LW, Becker-Dreps S, Simpore J, Hammarstrom L, Larson G, Svensson L (2014) Both Lewis and secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner. Clin Infect Dis 59:1567–1573PubMedPubMedCentralCrossRef Nordgren J, Sharma S, Bucardo F, Nasir W, Gunaydin G, Ouermi D, Nitiema LW, Becker-Dreps S, Simpore J, Hammarstrom L, Larson G, Svensson L (2014) Both Lewis and secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner. Clin Infect Dis 59:1567–1573PubMedPubMedCentralCrossRef
127.
go back to reference Novak D, Svennerholm AM (2015) A comparison of seasonal variations in rotavirus antibodies in the breast milk of Swedish and Bangladeshi mothers. Acta Paediatr 104:247–251PubMedCrossRef Novak D, Svennerholm AM (2015) A comparison of seasonal variations in rotavirus antibodies in the breast milk of Swedish and Bangladeshi mothers. Acta Paediatr 104:247–251PubMedCrossRef
128.
go back to reference O’Neal CM, Crawford SE, Estes MK, Conner ME (1997) Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol 71:8707–8717PubMedPubMedCentralCrossRef O’Neal CM, Crawford SE, Estes MK, Conner ME (1997) Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol 71:8707–8717PubMedPubMedCentralCrossRef
129.
go back to reference O’Ryan ML, Matson DO, Estes MK, Pickering LK (1994) Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. J Infect Dis 169:504–511PubMedCrossRef O’Ryan ML, Matson DO, Estes MK, Pickering LK (1994) Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. J Infect Dis 169:504–511PubMedCrossRef
130.
go back to reference O’Ryan ML, Matson DO, Estes MK, Pickering LK (1994) Acquisition of serum isotype-specific and G type-specific antirotavirus antibodies among children in day care centers. Pediatr Infect Dis J 13:890–895PubMedCrossRef O’Ryan ML, Matson DO, Estes MK, Pickering LK (1994) Acquisition of serum isotype-specific and G type-specific antirotavirus antibodies among children in day care centers. Pediatr Infect Dis J 13:890–895PubMedCrossRef
131.
go back to reference Offit P (1994) Immunologic determinants of protection against rotavirus disease. Curr Top Microbiol Immunol 185:229–254PubMed Offit P (1994) Immunologic determinants of protection against rotavirus disease. Curr Top Microbiol Immunol 185:229–254PubMed
133.
go back to reference Otero CE, Langel SN, Blasi M, Permar SR (2020) Maternal antibody interference contributes to reduced rotavirus vaccine efficacy in developing countries. PLoS Pathog 16:e1009010PubMedPubMedCentralCrossRef Otero CE, Langel SN, Blasi M, Permar SR (2020) Maternal antibody interference contributes to reduced rotavirus vaccine efficacy in developing countries. PLoS Pathog 16:e1009010PubMedPubMedCentralCrossRef
134.
go back to reference Parker EP, Ramani S, Lopman BA, Church JA, Iturriza-Gomara M, Prendergast AJ, Grassly NC (2018) Causes of impaired oral vaccine efficacy in developing countries. Future Microbiol 13:97–118PubMedCrossRef Parker EP, Ramani S, Lopman BA, Church JA, Iturriza-Gomara M, Prendergast AJ, Grassly NC (2018) Causes of impaired oral vaccine efficacy in developing countries. Future Microbiol 13:97–118PubMedCrossRef
135.
go back to reference Parker EPK, Praharaj I, Zekavati A, Lazarus RP, Giri S, Operario DJ, Liu J, Houpt E, Iturriza-Gomara M, Kampmann B, John J, Kang G, Grassly NC (2018) Influence of the intestinal microbiota on the immunogenicity of oral rotavirus vaccine given to infants in south India. Vaccine 36:264–272PubMedPubMedCentralCrossRef Parker EPK, Praharaj I, Zekavati A, Lazarus RP, Giri S, Operario DJ, Liu J, Houpt E, Iturriza-Gomara M, Kampmann B, John J, Kang G, Grassly NC (2018) Influence of the intestinal microbiota on the immunogenicity of oral rotavirus vaccine given to infants in south India. Vaccine 36:264–272PubMedPubMedCentralCrossRef
136.
go back to reference Parreno V, Bai M, Liu F, Jing J, Olney E, Li G, Wen K, Yang X, Castellucc TB, Kocher JF (2022) Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease. Vaccines 10:1529PubMedPubMedCentralCrossRef Parreno V, Bai M, Liu F, Jing J, Olney E, Li G, Wen K, Yang X, Castellucc TB, Kocher JF (2022) Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease. Vaccines 10:1529PubMedPubMedCentralCrossRef
137.
go back to reference Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U (2013) A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis 208:284–294PubMedCrossRef Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U (2013) A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis 208:284–294PubMedCrossRef
140.
go back to reference Pollock L, Bennett A, Jere KC, Mandolo J, Dube Q, Bar-Zeev N, Heyderman RS, Cunliffe NA, Iturriza-Gomara M (2022) Plasma rotavirus-specific IgA and risk of rotavirus vaccine failure in infants in Malawi. Clin Infect Dis 75:41–46PubMedCrossRef Pollock L, Bennett A, Jere KC, Mandolo J, Dube Q, Bar-Zeev N, Heyderman RS, Cunliffe NA, Iturriza-Gomara M (2022) Plasma rotavirus-specific IgA and risk of rotavirus vaccine failure in infants in Malawi. Clin Infect Dis 75:41–46PubMedCrossRef
141.
go back to reference Premkumar P, Lopman B, Ramani S, Paul A, Gladstone B, Muliyil J, Mukhopadhya I, Parashar U, Kang G (2014) Association of serum antibodies with protection against rotavirus infection and disease in South Indian children. Vaccine 32:A55–A61PubMedPubMedCentralCrossRef Premkumar P, Lopman B, Ramani S, Paul A, Gladstone B, Muliyil J, Mukhopadhya I, Parashar U, Kang G (2014) Association of serum antibodies with protection against rotavirus infection and disease in South Indian children. Vaccine 32:A55–A61PubMedPubMedCentralCrossRef
142.
go back to reference Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG (2007) A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 196:1304–1312PubMedCrossRef Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG (2007) A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 196:1304–1312PubMedCrossRef
143.
go back to reference Rath T, Kuo TT, Baker K, Qiao S-W, Kobayashi K, Yoshida M, Roopenian D, Fiebiger E, Lencer WI, Blumberg RS (2013) The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol 33:9–17CrossRef Rath T, Kuo TT, Baker K, Qiao S-W, Kobayashi K, Yoshida M, Roopenian D, Fiebiger E, Lencer WI, Blumberg RS (2013) The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol 33:9–17CrossRef
144.
go back to reference Rathi N, Desai S, Kawade A, Venkatramanan P, Kundu R, Lalwani SK, Dubey A, Rao JV, Narayanappa D, Ghildiyal R (2018) A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine 36:7943–7949PubMedPubMedCentralCrossRef Rathi N, Desai S, Kawade A, Venkatramanan P, Kundu R, Lalwani SK, Dubey A, Rao JV, Narayanappa D, Ghildiyal R (2018) A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine 36:7943–7949PubMedPubMedCentralCrossRef
145.
go back to reference Ray P, Malik J, Singh RK, Bhatnagar S, Bahl R, Kumar R, Bhan MK (2003) Rotavirus nonstructural protein NSP4 induces heterotypic antibody responses during natural infection in children. J Infect Dis 187:1786–1793PubMedCrossRef Ray P, Malik J, Singh RK, Bhatnagar S, Bahl R, Kumar R, Bhan MK (2003) Rotavirus nonstructural protein NSP4 induces heterotypic antibody responses during natural infection in children. J Infect Dis 187:1786–1793PubMedCrossRef
146.
go back to reference Resch TK, Wang Y, Moon S-S, Joyce J, Li S, Prausnitz M, Jiang B (2018) Inactivated rotavirus vaccine by parenteral administration induces mucosal immunity in mice. Sci Rep 8:561PubMedPubMedCentralCrossRef Resch TK, Wang Y, Moon S-S, Joyce J, Li S, Prausnitz M, Jiang B (2018) Inactivated rotavirus vaccine by parenteral administration induces mucosal immunity in mice. Sci Rep 8:561PubMedPubMedCentralCrossRef
147.
go back to reference Rojas A, Boher Y, Guntinas M, Perez-Schael I (1995) Homotypic immune response to primary infection with rotavirus serotype G1. J Med Virol 47:404–409PubMedCrossRef Rojas A, Boher Y, Guntinas M, Perez-Schael I (1995) Homotypic immune response to primary infection with rotavirus serotype G1. J Med Virol 47:404–409PubMedCrossRef
148.
go back to reference Rojas OL, González AM, González R, Pérez-Schael I, Greenberg HB, Franco MA, Angel J (2003) Human rotavirus specific T cells: quantification by ELISPOT and expression of homing receptors on CD4+ T cells. Virology 314:671–679PubMedCrossRef Rojas OL, González AM, González R, Pérez-Schael I, Greenberg HB, Franco MA, Angel J (2003) Human rotavirus specific T cells: quantification by ELISPOT and expression of homing receptors on CD4+ T cells. Virology 314:671–679PubMedCrossRef
149.
go back to reference Rongsen-Chandola T, Strand TA, Goyal N, Flem E, Rathore SS, Arya A, Winje BA, Lazarus R, Shanmugasundaram E, Babji S (2014) Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants. Vaccine 32:A134–A139PubMedCrossRef Rongsen-Chandola T, Strand TA, Goyal N, Flem E, Rathore SS, Arya A, Winje BA, Lazarus R, Shanmugasundaram E, Babji S (2014) Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants. Vaccine 32:A134–A139PubMedCrossRef
150.
go back to reference Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, Lopez P, Macias-Parra M, Ortega-Barria E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavia-Ruz N, Salmeron J, Ruttimann R, Tinoco JC, Rubio P, Nunez E, Guerrero ML, Yarzabal JP, Damaso S, Tornieporth N, Saez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O’Ryan M, Human Rotavirus Vaccine Study G (2006) Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354:11–22PubMedCrossRef Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, Lopez P, Macias-Parra M, Ortega-Barria E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavia-Ruz N, Salmeron J, Ruttimann R, Tinoco JC, Rubio P, Nunez E, Guerrero ML, Yarzabal JP, Damaso S, Tornieporth N, Saez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O’Ryan M, Human Rotavirus Vaccine Study G (2006) Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354:11–22PubMedCrossRef
151.
go back to reference Saluja T, Palkar S, Misra P, Gupta M, Venugopal P, Sood AK, Dhati RM, Shetty A, Dhaded SM, Agarkhedkar S (2017) Live attenuated tetravalent (G1–G4) bovine-human reassortant rotavirus vaccine (BRV-TV): randomized, controlled phase III study in Indian infants. Vaccine 35:3575–3581PubMedCrossRef Saluja T, Palkar S, Misra P, Gupta M, Venugopal P, Sood AK, Dhati RM, Shetty A, Dhaded SM, Agarkhedkar S (2017) Live attenuated tetravalent (G1–G4) bovine-human reassortant rotavirus vaccine (BRV-TV): randomized, controlled phase III study in Indian infants. Vaccine 35:3575–3581PubMedCrossRef
152.
go back to reference Santos SM, Ferreira TL, Quintal VS, Carbonare SB, Tino-De-Franco M (2013) Milk from Brazilian women presents secretory IgA antibodies and neutralizes rotavirus G9P [5]. Jornal de pediatria 89:510–513PubMedCrossRef Santos SM, Ferreira TL, Quintal VS, Carbonare SB, Tino-De-Franco M (2013) Milk from Brazilian women presents secretory IgA antibodies and neutralizes rotavirus G9P [5]. Jornal de pediatria 89:510–513PubMedCrossRef
153.
go back to reference Segovia MG (2018) Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from birth. Acta Pediatrica Espanola 76:62–63 Segovia MG (2018) Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from birth. Acta Pediatrica Espanola 76:62–63
154.
go back to reference Settembre EC, Chen JZ, Dormitzer PR, Grigorieff N, Harrison SC (2011) Atomic model of an infectious rotavirus particle. EMBO J 30:408–416PubMedCrossRef Settembre EC, Chen JZ, Dormitzer PR, Grigorieff N, Harrison SC (2011) Atomic model of an infectious rotavirus particle. EMBO J 30:408–416PubMedCrossRef
155.
go back to reference Shaw RD, Fong KJ, Losonsky GA, Levine MM, Maldonado Y, Yolken R, Flores J, Kapikian AZ, Vo PT, Greenberg HB (1987) Epitope-specific immune responses to rotavirus vaccination. Gastroenterology 93:941–950PubMedCrossRef Shaw RD, Fong KJ, Losonsky GA, Levine MM, Maldonado Y, Yolken R, Flores J, Kapikian AZ, Vo PT, Greenberg HB (1987) Epitope-specific immune responses to rotavirus vaccination. Gastroenterology 93:941–950PubMedCrossRef
156.
go back to reference Shin S, Anh DD, Zaman K, Yunus M, Thiem VD, Azim T, Victor JC, Dallas MJ, Steele AD, Neuzil KM (2012) Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine 30:A106–A113PubMedCrossRef Shin S, Anh DD, Zaman K, Yunus M, Thiem VD, Azim T, Victor JC, Dallas MJ, Steele AD, Neuzil KM (2012) Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine 30:A106–A113PubMedCrossRef
157.
go back to reference Shoja Z, Tagliamonte M, Jalilvand S, Mollaei-Kandelous Y, De Stradis A, Tornesello ML, Buonaguro FM, Buonaguro L (2015) Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines. J Med Virol 87:102–111PubMedCrossRef Shoja Z, Tagliamonte M, Jalilvand S, Mollaei-Kandelous Y, De Stradis A, Tornesello ML, Buonaguro FM, Buonaguro L (2015) Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines. J Med Virol 87:102–111PubMedCrossRef
158.
go back to reference Shoja Z, Jalilvand S, Latifi T, Roohvand F (2022) Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials. Arch Virol 167:1013–1023PubMedPubMedCentralCrossRef Shoja Z, Jalilvand S, Latifi T, Roohvand F (2022) Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials. Arch Virol 167:1013–1023PubMedPubMedCentralCrossRef
159.
go back to reference Sow SO, Tapia M, Haidara FC, Ciarlet M, Diallo F, Kodio M, Doumbia M, Dembélé RD, Traoré O, Onwuchekwa UU (2012) Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine 30:A71–A78PubMedCrossRef Sow SO, Tapia M, Haidara FC, Ciarlet M, Diallo F, Kodio M, Doumbia M, Dembélé RD, Traoré O, Onwuchekwa UU (2012) Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine 30:A71–A78PubMedCrossRef
160.
go back to reference Superti F, Ammendolia M, Valenti P, Seganti L (1997) Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med Microbiol Immunol 186:83–91PubMedCrossRef Superti F, Ammendolia M, Valenti P, Seganti L (1997) Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med Microbiol Immunol 186:83–91PubMedCrossRef
161.
go back to reference Svensson L, Sheshberadaran H, Vene S, Norrby E, Grandien M, Wadell G (1987) Serum antibody responses to individual viral polypeptides in human rotavirus infections. J Gen Virol 68:643–651PubMedCrossRef Svensson L, Sheshberadaran H, Vene S, Norrby E, Grandien M, Wadell G (1987) Serum antibody responses to individual viral polypeptides in human rotavirus infections. J Gen Virol 68:643–651PubMedCrossRef
162.
go back to reference Svensson L, Sheshberadaran H, Vesikari T, Norrby E, Wadell G (1987) Immune response to rotavirus polypeptides after vaccination with heterologous rotavirus vaccines (RIT 4237, RRV-1). J Gen Virol 68:1993–1999PubMedCrossRef Svensson L, Sheshberadaran H, Vesikari T, Norrby E, Wadell G (1987) Immune response to rotavirus polypeptides after vaccination with heterologous rotavirus vaccines (RIT 4237, RRV-1). J Gen Virol 68:1993–1999PubMedCrossRef
163.
go back to reference Taniguchi K, Urasawa T, Kobayashi N, Ahmed M, Adachi N, Chiba S, Urasawa S (1991) Antibody response to serotype-specific and cross-reactive neutralization epitopes on VP4 and VP7 after rotavirus infection or vaccination. J Clin Microbiol 29:483–487PubMedPubMedCentralCrossRef Taniguchi K, Urasawa T, Kobayashi N, Ahmed M, Adachi N, Chiba S, Urasawa S (1991) Antibody response to serotype-specific and cross-reactive neutralization epitopes on VP4 and VP7 after rotavirus infection or vaccination. J Clin Microbiol 29:483–487PubMedPubMedCentralCrossRef
164.
go back to reference Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis KD, Sow SO, Rivers SB, Levine MM, Laserson KF, Feikin DR (2012) Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine 30:A79–A85PubMedCrossRef Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis KD, Sow SO, Rivers SB, Levine MM, Laserson KF, Feikin DR (2012) Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine 30:A79–A85PubMedCrossRef
165.
go back to reference Tate JE, Burton AH, Boschi-Pinto C, Parashar UD, Network WHOCGRS, Agocs M, Serhan F, de Oliveira L, Mwenda JM, Mihigo R (2016) Global, regional, and national estimates of rotavirus mortality in children< 5 years of age, 2000–2013. Clin Infect Dis 62:S96–S105PubMedCrossRef Tate JE, Burton AH, Boschi-Pinto C, Parashar UD, Network WHOCGRS, Agocs M, Serhan F, de Oliveira L, Mwenda JM, Mihigo R (2016) Global, regional, and national estimates of rotavirus mortality in children< 5 years of age, 2000–2013. Clin Infect Dis 62:S96–S105PubMedCrossRef
166.
go back to reference Thiem VD, Anh DD, Ha VH, Hien ND, Huong NT, Nga NT, Thang TC, McNeal MM, Meyer N, Pham HL, Huong NM, Gompana G, Cassels F, Tang Y, Flores J, Rathi N (2021) Safety and immunogenicity of two formulations of rotavirus vaccine in Vietnamese infants. Vaccine 39:4463–4470PubMedCrossRef Thiem VD, Anh DD, Ha VH, Hien ND, Huong NT, Nga NT, Thang TC, McNeal MM, Meyer N, Pham HL, Huong NM, Gompana G, Cassels F, Tang Y, Flores J, Rathi N (2021) Safety and immunogenicity of two formulations of rotavirus vaccine in Vietnamese infants. Vaccine 39:4463–4470PubMedCrossRef
167.
go back to reference Tino De Franco M, Vieira P, Santos S, Ferreira T, Araújo E, Quintal V, Carbonare SB (2013) Neutralizing activity and secretory IgA antibodies reactive with rotavirus SA-11 (serotype G3) in colostrum and milk from Brazilian women. Paediatr Int Child Health 33:102–107PubMedCrossRef Tino De Franco M, Vieira P, Santos S, Ferreira T, Araújo E, Quintal V, Carbonare SB (2013) Neutralizing activity and secretory IgA antibodies reactive with rotavirus SA-11 (serotype G3) in colostrum and milk from Brazilian women. Paediatr Int Child Health 33:102–107PubMedCrossRef
168.
go back to reference Trang NV, Braeckman T, Lernout T, Hau VT, Anh LT, Luan LT, Van Damme P, Anh DD (2014) Prevalence of rotavirus antibodies in breast milk and inhibitory effects to rotavirus vaccines. Hum Vaccin Immunother 10:3681–3687PubMedCrossRef Trang NV, Braeckman T, Lernout T, Hau VT, Anh LT, Luan LT, Van Damme P, Anh DD (2014) Prevalence of rotavirus antibodies in breast milk and inhibitory effects to rotavirus vaccines. Hum Vaccin Immunother 10:3681–3687PubMedCrossRef
169.
go back to reference Tregnaghi MW, Abate HJ, Valencia A, Lopez P, Da Silveira TR, Rivera L, Medina DMR, Saez-Llorens X, Ayala SEG, De León T (2011) Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J 30:e103–e108PubMedCrossRef Tregnaghi MW, Abate HJ, Valencia A, Lopez P, Da Silveira TR, Rivera L, Medina DMR, Saez-Llorens X, Ayala SEG, De León T (2011) Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J 30:e103–e108PubMedCrossRef
170.
go back to reference Troeger C, Khalil IA, Rao PC, Cao S, Blacker BF, Ahmed T, Armah G, Bines JE, Brewer TG, Colombara DV (2018) Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr 172:958–965PubMedPubMedCentralCrossRef Troeger C, Khalil IA, Rao PC, Cao S, Blacker BF, Ahmed T, Armah G, Bines JE, Brewer TG, Colombara DV (2018) Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr 172:958–965PubMedPubMedCentralCrossRef
171.
go back to reference Twitchell EL, Tin C, Wen K, Zhang H, Becker-Dreps S, Azcarate-Peril MA, Vilchez S, Li G, Ramesh A, Weiss M (2016) Modeling human enteric dysbiosis and rotavirus immunity in gnotobiotic pigs. Gut Pathog 8:1–18CrossRef Twitchell EL, Tin C, Wen K, Zhang H, Becker-Dreps S, Azcarate-Peril MA, Vilchez S, Li G, Ramesh A, Weiss M (2016) Modeling human enteric dysbiosis and rotavirus immunity in gnotobiotic pigs. Gut Pathog 8:1–18CrossRef
172.
go back to reference Vega CG, Bok M, Vlasova AN, Chattha KS, Gómez-Sebastián S, Nuñez C, Alvarado C, Lasa R, Escribano JM, Garaicoechea LL (2013) Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea. PLoS Pathog 9:e1003334PubMedPubMedCentralCrossRef Vega CG, Bok M, Vlasova AN, Chattha KS, Gómez-Sebastián S, Nuñez C, Alvarado C, Lasa R, Escribano JM, Garaicoechea LL (2013) Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea. PLoS Pathog 9:e1003334PubMedPubMedCentralCrossRef
173.
go back to reference Velasquez DE, Wang Y, Jiang B (2015) Inactivated human rotavirus vaccine induces heterotypic antibody response: correction and development of IgG avidity assay. Hum Vaccin Immunother 11:531–533PubMedPubMedCentralCrossRef Velasquez DE, Wang Y, Jiang B (2015) Inactivated human rotavirus vaccine induces heterotypic antibody response: correction and development of IgG avidity assay. Hum Vaccin Immunother 11:531–533PubMedPubMedCentralCrossRef
174.
go back to reference Velasquez DE, Parashar U, Jiang B (2018) Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors. Expert Rev Vaccines 17:145–161PubMed Velasquez DE, Parashar U, Jiang B (2018) Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors. Expert Rev Vaccines 17:145–161PubMed
175.
go back to reference Velázquez FR, Matson DO, Calva JJ, Guerrero ML, Morrow AL, Carter-Campbell S, Glass RI, Estes MK, Pickering LK, Ruiz-Palacios GM (1996) Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 335:1022–1028PubMedCrossRef Velázquez FR, Matson DO, Calva JJ, Guerrero ML, Morrow AL, Carter-Campbell S, Glass RI, Estes MK, Pickering LK, Ruiz-Palacios GM (1996) Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 335:1022–1028PubMedCrossRef
176.
go back to reference Velázquez FR, Matson DO, Guerrero ML, Shults J, Calva JJ, Morrow AL, Glass RI, Pickering LK, Ruiz-Palacios GM (2000) Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 182:1602–1609PubMedCrossRef Velázquez FR, Matson DO, Guerrero ML, Shults J, Calva JJ, Morrow AL, Glass RI, Pickering LK, Ruiz-Palacios GM (2000) Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 182:1602–1609PubMedCrossRef
177.
go back to reference Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schodel F, Karvonen A, Drummond JE, DiNubile MJ, Heaton PM (2006) Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 24:4821–4829PubMedCrossRef Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schodel F, Karvonen A, Drummond JE, DiNubile MJ, Heaton PM (2006) Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 24:4821–4829PubMedCrossRef
178.
go back to reference Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB (2006) Safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354:23–33PubMedCrossRef Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB (2006) Safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354:23–33PubMedCrossRef
179.
go back to reference Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Coia M, Cook JR, Koch G, Heaton P (2007) Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis 11:S29–S35PubMedCrossRef Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Coia M, Cook JR, Koch G, Heaton P (2007) Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis 11:S29–S35PubMedCrossRef
180.
go back to reference Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor J, Cohen R, Meurice F, Han H, Damaso S, Bouckenooghe A (2007) Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 370:1757–1763PubMedCrossRef Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor J, Cohen R, Meurice F, Han H, Damaso S, Bouckenooghe A (2007) Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 370:1757–1763PubMedCrossRef
181.
go back to reference Vizzi E, Calvino E, Gonzalez R, Perez-Schael I, Ciarlet M, Kang G, Estes MK, Liprandi F, Ludert JE (2005) Evaluation of serum antibody responses against the rotavirus nonstructural protein NSP4 in children after rhesus rotavirus tetravalent vaccination or natural infection. Clin Diagn Lab Immunol 12:1157–1163PubMedPubMedCentral Vizzi E, Calvino E, Gonzalez R, Perez-Schael I, Ciarlet M, Kang G, Estes MK, Liprandi F, Ludert JE (2005) Evaluation of serum antibody responses against the rotavirus nonstructural protein NSP4 in children after rhesus rotavirus tetravalent vaccination or natural infection. Clin Diagn Lab Immunol 12:1157–1163PubMedPubMedCentral
182.
go back to reference Vlasova AN, Rajashekara G, Saif LJ (2018) Interactions between human microbiome, diet, enteric viruses and immune system: Novel insights from gnotobiotic pig research. Drug Discov Today Dis Models 28:95–103PubMedPubMedCentralCrossRef Vlasova AN, Rajashekara G, Saif LJ (2018) Interactions between human microbiome, diet, enteric viruses and immune system: Novel insights from gnotobiotic pig research. Drug Discov Today Dis Models 28:95–103PubMedPubMedCentralCrossRef
183.
go back to reference Wandera EA, Mohammad S, Komoto S, Maeno Y, Nyangao J, Ide T, Kathiiko C, Odoyo E, Tsuji T, Taniguchi K, Ichinose Y (2017) Molecular epidemiology of rotavirus gastroenteritis in Central Kenya before vaccine introduction, 2009–2014. J Med Virol 89:809–817PubMedCrossRef Wandera EA, Mohammad S, Komoto S, Maeno Y, Nyangao J, Ide T, Kathiiko C, Odoyo E, Tsuji T, Taniguchi K, Ichinose Y (2017) Molecular epidemiology of rotavirus gastroenteritis in Central Kenya before vaccine introduction, 2009–2014. J Med Virol 89:809–817PubMedCrossRef
184.
go back to reference Wang Y, Azevedo M, Saif LJ, Gentsch JR, Glass RI, Jiang B (2010) Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. Vaccine 28:5432–5436PubMedCrossRef Wang Y, Azevedo M, Saif LJ, Gentsch JR, Glass RI, Jiang B (2010) Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. Vaccine 28:5432–5436PubMedCrossRef
185.
go back to reference Wang Y, Vlasova A, Velasquez DE, Saif LJ, Kandasamy S, Kochba E, Levin Y, Jiang B (2016) Skin vaccination against rotavirus using microneedles: proof of concept in gnotobiotic piglets. PLoS ONE 11:e0166038PubMedPubMedCentralCrossRef Wang Y, Vlasova A, Velasquez DE, Saif LJ, Kandasamy S, Kochba E, Levin Y, Jiang B (2016) Skin vaccination against rotavirus using microneedles: proof of concept in gnotobiotic piglets. PLoS ONE 11:e0166038PubMedPubMedCentralCrossRef
186.
go back to reference Ward RL, Bernstein DI, Shukla R, Young EC, Sherwood JR, McNeal MM, Walker MC, Schiff GM (1989) Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis 159:79–88PubMedCrossRef Ward RL, Bernstein DI, Shukla R, Young EC, Sherwood JR, McNeal MM, Walker MC, Schiff GM (1989) Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis 159:79–88PubMedCrossRef
187.
go back to reference Ward RL, Clemens JD, Knowlton DR, Rao MR, Van Loon FP, Huda N, Ahmed F, Schiff GM, Sack DA (1992) Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody. J Infect Dis 166:1251–1257PubMedCrossRef Ward RL, Clemens JD, Knowlton DR, Rao MR, Van Loon FP, Huda N, Ahmed F, Schiff GM, Sack DA (1992) Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody. J Infect Dis 166:1251–1257PubMedCrossRef
188.
go back to reference Westerman LE, McClure HM, Jiang B, Almond JW, Glass RI (2005) Serum IgG mediates mucosal immunity against rotavirus infection. Proc Natl Acad Sci 102:7268–7273PubMedPubMedCentralCrossRef Westerman LE, McClure HM, Jiang B, Almond JW, Glass RI (2005) Serum IgG mediates mucosal immunity against rotavirus infection. Proc Natl Acad Sci 102:7268–7273PubMedPubMedCentralCrossRef
189.
go back to reference White LJ, Buttery J, Cooper B, Nokes DJ, Medley G (2008) Rotavirus within day care centres in Oxfordshire, UK: characterization of partial immunity. J R Soc Interface 5:1481–1490PubMedPubMedCentralCrossRef White LJ, Buttery J, Cooper B, Nokes DJ, Medley G (2008) Rotavirus within day care centres in Oxfordshire, UK: characterization of partial immunity. J R Soc Interface 5:1481–1490PubMedPubMedCentralCrossRef
190.
go back to reference WHO (2009) Rotavirus vaccines: an update. Wkly Epidemiol Rec Relevé épidémiologique hebdomadaire 84:533–540 WHO (2009) Rotavirus vaccines: an update. Wkly Epidemiol Rec Relevé épidémiologique hebdomadaire 84:533–540
191.
go back to reference Witte D, Handley A, Jere KC, Bogandovic-Sakran N, Mpakiza A, Turner A, Pavlic D, Boniface K, Mandolo J, Ong DS (2022) Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study. Lancet Infect Dis 22:668–678PubMedPubMedCentralCrossRef Witte D, Handley A, Jere KC, Bogandovic-Sakran N, Mpakiza A, Turner A, Pavlic D, Boniface K, Mandolo J, Ong DS (2022) Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study. Lancet Infect Dis 22:668–678PubMedPubMedCentralCrossRef
192.
go back to reference Xia S, Du J, Su J, Liu Y, Huang L, Yu Q, Xie Z, Gao J, Xu B, Gao X (2020) Efficacy, immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus vaccine (LLR3) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine 38:7393–7400PubMedCrossRef Xia S, Du J, Su J, Liu Y, Huang L, Yu Q, Xie Z, Gao J, Xu B, Gao X (2020) Efficacy, immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus vaccine (LLR3) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine 38:7393–7400PubMedCrossRef
193.
go back to reference Xie L, Yan M, Wang X, Ye J, Mi K, Yan S, Niu X, Li H, Sun M (2015) Immunogenicity and efficacy in mice of an adenovirus-based bicistronic rotavirus vaccine expressing NSP4 and VP7. Virus Res 210:298–307PubMedCrossRef Xie L, Yan M, Wang X, Ye J, Mi K, Yan S, Niu X, Li H, Sun M (2015) Immunogenicity and efficacy in mice of an adenovirus-based bicistronic rotavirus vaccine expressing NSP4 and VP7. Virus Res 210:298–307PubMedCrossRef
194.
go back to reference Yuan L, Geyer A, Hodgins DC, Fan Z, Qian Y, Chang K-O, Crawford SE, Parreño V, Ward LA, Estes MK (2000) Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J Virol 74:8843–8853PubMedPubMedCentralCrossRef Yuan L, Geyer A, Hodgins DC, Fan Z, Qian Y, Chang K-O, Crawford SE, Parreño V, Ward LA, Estes MK (2000) Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J Virol 74:8843–8853PubMedPubMedCentralCrossRef
195.
go back to reference Yuan L, Saif LJ (2002) Induction of mucosal immune responses and protection against enteric viruses: rotavirus infection of gnotobiotic pigs as a model. Vet Immunol Immunopathol 87:147–160PubMedPubMedCentralCrossRef Yuan L, Saif LJ (2002) Induction of mucosal immune responses and protection against enteric viruses: rotavirus infection of gnotobiotic pigs as a model. Vet Immunol Immunopathol 87:147–160PubMedPubMedCentralCrossRef
196.
go back to reference Yuan L, Azevedo MS, Gonzalez AM, Jeong K-i, Van Nguyen T, Lewis P, Iosef C, Herrmann JE, Saif LJ (2005) Mucosal and systemic antibody responses and protection induced by a prime/boost rotavirus-DNA vaccine in a gnotobiotic pig model. Vaccine 23:3925–3936PubMedCrossRef Yuan L, Azevedo MS, Gonzalez AM, Jeong K-i, Van Nguyen T, Lewis P, Iosef C, Herrmann JE, Saif LJ (2005) Mucosal and systemic antibody responses and protection induced by a prime/boost rotavirus-DNA vaccine in a gnotobiotic pig model. Vaccine 23:3925–3936PubMedCrossRef
197.
go back to reference Zaman K, Anh DD, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Thiem VD, Mai LTP, Luby SP, Tho LH, Coia ML, Lewis K, Rivers SB, Sack DA, Schödel F, Steele AD, Neuzil KM, Ciarlet M (2010) Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 376:615–623PubMedCrossRef Zaman K, Anh DD, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Thiem VD, Mai LTP, Luby SP, Tho LH, Coia ML, Lewis K, Rivers SB, Sack DA, Schödel F, Steele AD, Neuzil KM, Ciarlet M (2010) Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 376:615–623PubMedCrossRef
Metadata
Title
Correlates of immune protection against human rotaviruses: natural infection and vaccination
Authors
Tayebeh Latifi
Atefeh Kachooei
Somayeh Jalilvand
Saman Zafarian
Farzin Roohvand
Zabihollah Shoja
Publication date
01-03-2024
Publisher
Springer Vienna
Keyword
Vaccination
Published in
Archives of Virology / Issue 3/2024
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-024-05975-y

Other articles of this Issue 3/2024

Archives of Virology 3/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.